CJC 1295 is a peptide of 29 amino acid length, primarily functioning as a growth hormone releasing hormone (GHRH) analog. CJC-1295 represents a very exciting new compound that has the potential to increase growth hormone and IGF-I secretion and effects. CJC - 1295 Stimulates GH and IGF-1 Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to intense fat loss, and increases protein synthesis for more muscle growth.

CJC-1295 is a synthetic modification of growth hormone releasing factor (GRF) with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. These substitutions create a much more stable peptide. By applying the Drug Affinity Complex (DAC) technology to GRF, the peptide selectively and covalently binds to circulating albumin after subcutaneous (SC) administration, thus prolonging its half-life.

These substitutions are key to increasing the overall half life of CJC-1295 but there lies an even greater reason as to why the half life has been extended. Bioconjugation is a relatively newer technology that takes a reactive group and attaches it to a peptide, which in turn reacts with a nucleophilic (usually a partially negative molecule) entity found in the blood to form a more stable bond.

In fact, bioconjugation is so effective that there was less than 1% of CJC-1295 left unreacted in vivo and over 90% was stabilized after subcutaneous injection. This means that you get more of what you paid for working for you.

With an increased half life CJC-1295 can provide intense fat loss along with increased protein synthesis for even more muscle growth. CJC-1295 is an exciting compound that we are proud to offer our clients.